Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 6241 AL 6255

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO, Cocke PJ, Greg Hall D, Friedrich S, Citron M, Audia JE.

J Neurosci. 2011 Nov 16;31(46):16507-16. doi: 10.1523/JNEUROSCI.3647-11.2011.

Targeting post-translational modifications on tau as a therapeutic strategy for Alzheimer's disease

Marcus JN, Schachter J.

J Neurogenet. 2011 Dec;25(4):127-33. doi: 10.3109/01677063.2011.626471.

Does memantine improve the gait of individuals with Alzheimer's disease?

Beauchet O, Allali G, Launay C, Fantino B, Annweiler C.

J Am Geriatr Soc. 2011 Nov;59(11):2181-2. doi: 10.1111/j.1532-5415.2011.03648.x.

Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease

Percy ME, Kruck TP, Pogue AI, Lukiw WJ.

J Inorg Biochem. 2011 Nov;105(11):1505-12. doi: 10.1016/j.jinorgbio.2011.08.001. Epub 2011 Aug 19.

Toward a unifying hypothesis in the development of Alzheimer's disease

Balin B, Abrams JT, Schrogie J.

CNS Neurosci Ther. 2011 Dec;17(6):587-9. doi: 10.1111/j.1755-5949.2011.00269.x.

γ-Secretase inhibitors and modulators for Alzheimer's disease

Wolfe MS.

J Neurochem. 2012 Jan;120 Suppl 1(Suppl 1):89-98. doi: 10.1111/j.1471-4159.2011.07501.x. Epub 2011 Nov 28.

Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease?

Nalivaeva NN, Beckett C, Belyaev ND, Turner AJ.

J Neurochem. 2012 Jan;120 Suppl 1:167-185. doi: 10.1111/j.1471-4159.2011.07510.x. Epub 2011 Nov 28.

Regulation of β-site APP-cleaving enzyme 1 gene expression and its role in Alzheimer's disease

Sun X, Bromley-Brits K, Song W.

J Neurochem. 2012 Jan;120 Suppl 1:62-70. doi: 10.1111/j.1471-4159.2011.07515.x. Epub 2011 Nov 28.

Developing β-secretase inhibitors for treatment of Alzheimer's disease

Ghosh AK, Brindisi M, Tang J.

J Neurochem. 2012 Jan;120 Suppl 1(Suppl 1):71-83. doi: 10.1111/j.1471-4159.2011.07476.x. Epub 2011 Nov 28.

[Role of the blood-brain barrier in Alzheimer's disease]

Gosselet F, Candela P, Cecchelli R, Fenart L.

Med Sci (Paris). 2011 Nov;27(11):987-92. doi: 10.1051/medsci/20112711015. Epub 2011 Nov 30.

Testing the right target and right drug at the right stage

Sperling RA, Jack CR Jr, Aisen PS.

Sci Transl Med. 2011 Nov 30;3(111):111cm33. doi: 10.1126/scitranslmed.3002609.

Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer's disease

Choi DY, Lee YJ, Hong JT, Lee HJ.

Brain Res Bull. 2012 Feb 10;87(2-3):144-53. doi: 10.1016/j.brainresbull.2011.11.014. Epub 2011 Nov 28.

Characterization of oral disintegrating film containing donepezil for Alzheimer disease

Liew KB, Tan YT, Peh KK.

AAPS PharmSciTech. 2012 Mar;13(1):134-42. doi: 10.1208/s12249-011-9729-4. Epub 2011 Dec 14.

Defining the mechanism of action of 4-phenylbutyrate to develop a small-molecule-based therapy for Alzheimer's disease

Cuadrado-Tejedor M, García-Osta A, Ricobaraza A, Oyarzabal J, Franco R.

Curr Med Chem. 2011;18(36):5545-53. doi: 10.2174/092986711798347315.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias